Fig. 2.

62-year-old male patient with a hepatocellular carcinoma developed on HCV-related cirrhosis.

Baseline contrast-enhanced CT (arterial phase) showed a large tumour located in the left liver, with heterogeneous hyperenhancement on arterial phase, consistent with tumour viability. The patient underwent 1 session of chemoembolisation with drug-eluting beads containing idarubicin. One-month follow-up contrast-enhanced CT showed no change in tumour size but significant decrease of viable areas (i.e. showing contrast enhancement). mRECIST showed >30% decrease in the largest diameter of viable areas corresponding to a partial response. EASL criteria showed a >50% decrease in the cross-product of the 2 largest diameters of viable area, also corresponding to a partial response. The persistence of enhancing areas at the periphery of the treated tumour corresponds to TR-viable according to the LI-RADS response algorithm. EASL, European Association for the Study of the Liver criteria; LI-RADS, Liver Imaging Reporting And Data System; (m)RECIST, (modified) Response Evaluation Criteria in Solid Tumours.